Your browser is no longer supported. Please, upgrade your browser.
Settings
YMAB Y-mAbs Therapeutics, Inc. daily Stock Chart
YMAB [NASD]
Y-mAbs Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.51 Insider Own13.90% Shs Outstand39.72M Perf Week3.91%
Market Cap1.31B Forward P/E- EPS next Y-1.99 Insider Trans-0.29% Shs Float27.76M Perf Month6.01%
Income-72.00M PEG- EPS next Q-0.67 Inst Own42.30% Short Float3.83% Perf Quarter21.75%
Sales- P/S- EPS this Y-156.10% Inst Trans2.67% Short Ratio3.74 Perf Half Y44.73%
Book/sh2.50 P/B13.19 EPS next Y14.60% ROA-55.20% Target Price38.50 Perf Year43.04%
Cash/sh2.47 P/C13.34 EPS next 5Y- ROE-62.50% 52W Range18.60 - 34.49 Perf YTD5.50%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-4.42% Beta-
Dividend %- Quick Ratio7.10 Sales past 5Y- Gross Margin- 52W Low77.26% ATR1.59
Employees32 Current Ratio7.10 Sales Q/Q- Oper. Margin- RSI (14)60.48 Volatility4.91% 5.10%
OptionableNo Debt/Eq0.00 EPS Q/Q-98.70% Profit Margin- Rel Volume0.52 Prev Close32.62
ShortableYes LT Debt/Eq0.00 EarningsFeb 12 AMC Payout- Avg Volume284.45K Price32.97
Recom1.40 SMA205.20% SMA506.28% SMA20025.37% Volume149,190 Change1.07%
Dec-24-19Initiated JP Morgan Overweight $39
Nov-20-19Initiated Guggenheim Buy
Sep-04-19Initiated Wedbush Outperform
Apr-01-19Initiated H.C. Wainwright Buy $36
Oct-16-18Initiated BTIG Research Buy $35
Oct-16-18Initiated BofA/Merrill Buy $26
Jan-07-20 09:00AM  Y-mAbs Therapeutics To Present At 38th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-24-19 08:13AM  Benzinga Pro's Top 5 Stocks To Watch For Tues., Dec. 24, 2019: TSLA, WCC, ACST, YMAB, ITCI Benzinga
Dec-16-19 01:48PM  Is Y-mAbs Therapeutics, Inc. (YMAB) A Good Stock To Buy? Insider Monkey
Dec-12-19 09:00AM  Y-mAbs GD2-GD3 Vaccine Granted Rare Pediatric Disease Designation GlobeNewswire
Dec-11-19 09:00AM  Y-mAbs Announces Positive Naxitamab Frontline Data GlobeNewswire
Dec-05-19 04:01PM  Y-mAbs and the European Medicines Agency Pediatric Committee Reach Agreement on the Pediatric Investigation Plan for Omburtamab GlobeNewswire
09:00AM  Y-mAbs to Host R&D Event and Live Webcast on Wednesday, December 11 GlobeNewswire
Nov-29-19 09:00AM  Y-mAbs Initiates Rolling Submission of Biologics License Application to U.S. FDA for Naxitamab for Treatment of Neuroblastoma GlobeNewswire
Nov-15-19 09:03AM  Y-mAbs Announces Update on Omburtamab in DSRCT GlobeNewswire
Nov-13-19 04:01PM  Y-mAbs Announces Third Quarter 2019 Financial Results and Recent Corporate Developments GlobeNewswire
Nov-06-19 04:05PM  Y-mAbs to Announce Third Quarter 2019 Financial and Operating Results on November 13 GlobeNewswire
Nov-01-19 04:05PM  Y-mAbs Announces Closing of Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares GlobeNewswire -5.62%
11:00AM  Y-mAbs Flags Potential Delay In Pre-BLA Meeting, Sticks To Regulatory Filing Timeline Benzinga
Oct-30-19 08:20PM  Heres What Hedge Funds Think About Y-mAbs Therapeutics, Inc. (YMAB) Insider Monkey -10.13%
Oct-29-19 09:14PM  Y-mAbs Announces Pricing of Public Offering of Common Stock GlobeNewswire
04:40PM  Y-mAbs Announces Proposed Public Offering of Common Stock GlobeNewswire
07:32AM  The Daily Biotech Pulse: Mirati Tastes Success With KRAS Inhibitor, Roche-Spark Deal Delayed Further, Morphosys Halts Study Benzinga
Oct-28-19 10:42AM  We're Not Very Worried About Y-mAbs Therapeutics's (NASDAQ:YMAB) Cash Burn Rate Simply Wall St.
09:00AM  Y-mAbs Announces Positive Omburtamab Clinical Data GlobeNewswire
Oct-25-19 09:14AM  Y-mAbs Announces Naxitamab Update GlobeNewswire
Sep-04-19 03:09PM  Wedbush: Y-mAbs Could Attract Investor Attention As Market Volatility Grows Benzinga
Aug-30-19 09:00AM  Y-mAbs Announces Data to be Presented at 2019 CTOS GlobeNewswire
Aug-14-19 10:23PM  YmAbs Therapeutics, Inc. (YMAB) Q2 2019 Earnings Call Transcript Motley Fool
04:05PM  Y-mAbs Announces Second Quarter 2019 Financial Results and Recent Corporate Developments GlobeNewswire
Aug-08-19 01:36PM  How Much Of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Do Insiders Own? Simply Wall St.
Aug-07-19 04:15PM  Y-mAbs to Announce Second Quarter 2019 Financial and Operating Results on August 14 GlobeNewswire
Jul-08-19 09:00AM  Y-mAbs Announces Successful Pre-BLA Meeting with FDA for Naxitamab GlobeNewswire
Jul-01-19 09:01AM  Y-mAbs Announces Recruitment Status for Pivotal Trials GlobeNewswire
09:00AM  Y-mAbs Secures Commercial Radiolabeling Capacity GlobeNewswire
Jun-26-19 09:00AM  Y-mAbs Announces Data to be Presented at 2019 SIOP GlobeNewswire
May-15-19 05:00PM  Y-mAbs Announces Data to be Presented at 2019 ASCO Annual Meeting GlobeNewswire +5.71%
May-14-19 09:30AM  Y-mAbs Announces Development Update on Cancer Vaccine Program GlobeNewswire
May-10-19 04:01PM  Y-mAbs Announces First Quarter 2019 Financial Results and Recent Corporate Developments GlobeNewswire
May-08-19 08:45AM  Y-mAbs Therapeutics To Present at the Bank of America Merrill Lynch Healthcare Conference in Las Vegas GlobeNewswire
May-07-19 11:19AM  Heres What Hedge Funds Think About Y-mAbs Therapeutics, Inc. (YMAB) Insider Monkey
Apr-03-19 09:00AM  Y-mAbs Therapeutics To Present At The H.C. Wainwright Global Life Sciences Conference in London GlobeNewswire
Mar-30-19 10:18AM  Have Insiders Been Buying Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares? Simply Wall St.
Mar-22-19 04:15PM  Y-mAbs Announces 2018 Financial Results and Corporate Development Highlights GlobeNewswire
Mar-08-19 09:03AM  Y-mAbs Therapeutics To Present At Cowens 39th Annual Health Care Conference GlobeNewswire
Feb-13-19 09:00AM  Y-mAbs Therapeutics to Present at PEGS Boston GlobeNewswire
Dec-20-18 08:28AM  What Kind Of Investor Owns Most Of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)? Simply Wall St.
Dec-13-18 03:24PM  Y-mAbs Therapeutics To Present At 37th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-11-18 05:04PM  Y-mAbs Announces Appointment of Gérard Ber to its Board of Directors and Planned Departure of Michael Buschle GlobeNewswire
Dec-10-18 05:39PM  Y-mAbs Therapeutics Announces FDA Clearance of IND for its Bispecific GD2 Antibody GlobeNewswire
Nov-13-18 09:28AM  Y-mAbs Announces Third Quarter 2018 Financial Results and Recent Corporate Developments GlobeNewswire
Nov-01-18 09:00AM  Bispecific GD2 Antibody In Vivo Data to be Presented at ASH GlobeNewswire
Oct-23-18 09:20AM  Naxitamab Receives Positive Opinion for Orphan Medicinal Product Designation Approval in the EU GlobeNewswire
Sep-25-18 04:39PM  Y-mAbs Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire -6.27%
Sep-21-18 11:09AM  Y-mAbs' stock soars above IPO price in its public debut MarketWatch
07:22AM  Pediatric cancer biotech Y-mAbs Therapeutics raises $96 million in IPO MarketWatch
07:13AM  [$$] Y-mAbs Therapeutics Sells Extra Shares in IPO The Wall Street Journal
Sep-20-18 08:25PM  Y-mAbs Therapeutics Announces Pricing of Initial Public Offering GlobeNewswire
Y-mAbs Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment cancer in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system, leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. The company has a license and research collaboration agreement with Memorial Sloan Kettering Cancer Center. Y-mAbs Therapeutics, Inc. was founded in 2015 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
HEALY JAMESDirectorJan 15Option Exercise14.3525,778370,00225,778Jan 17 09:23 PM
Gad ThomasPresident & ChairmanJan 13Sale30.904,000123,612856,000Jan 15 04:20 PM
Gad ThomasPresident and ChairmanDec 16Sale31.544,000126,176860,000Dec 17 04:06 PM
Gad ThomasPresident and ChairmanDec 02Sale32.484,000129,930872,000Dec 04 04:05 PM
Gad ThomasPresident and ChairmanNov 18Sale28.414,000113,658876,000Nov 19 04:05 PM